8.A.23.1.39
Receptor tyrosine-protein kinase ErbB-2/ErbB-3. ErbB-2 is also called ERBB2, HER2, MLN19, NEU and NGL. It is of 1255 aas and possibly 2 TMSs, one at the N-terminus, and one large hydrophobic peak in the C-terminal half of the protein. ErbB-3 is also called HER3 and is of 1342 aas with at least one TMS near residue 650, but maybe also an N-terminal TMS. These two proteins form a complex with SorLA (TC# 9.B.87.1.17) (Al-Akhrass et al. 2021). They are parts of several cell surface receptor
complexes that apparently need a coreceptor for ligand binding. They are essential components of a neuregulin-receptor complex (Ieguchi et al. 2010). Expression profiling has identified TRPM7 and HER2 as potential targets for the combined treatment of cancer cells (Egawa et al. 2024). Other protein constituents of this ErbB2 signalling complex may include PMCA2 or ATP2B2 (TC# 3.a.3.2.40), Ezrin (TC# 8.A.25.1.1), Erbin (LAP2; Q96RT1; 1412 aas) and NHERF1 or NHE-RF1 (SLC9A3R1), TC# 8.A.24.1.1).
|
| Accession Number: | P21860 |
|---|
| Protein Name: | Receptor tyrosine-protein kinase erbB-3 |
|---|
| Length: | 1342 |
|---|
| Molecular Weight: | 148098.00 |
|---|
| Species: | Homo sapiens (Human) [9606] |
|---|
| Number of TMSs: | 1 |
|---|
| Location1 / Topology2 / Orientation3: |
Secreted1 |
|---|
| Substrate |
|
|---|
1: MRANDALQVL GLLFSLARGS EVGNSQAVCP GTLNGLSVTG DAENQYQTLY KLYERCEVVM
61: GNLEIVLTGH NADLSFLQWI REVTGYVLVA MNEFSTLPLP NLRVVRGTQV YDGKFAIFVM
121: LNYNTNSSHA LRQLRLTQLT EILSGGVYIE KNDKLCHMDT IDWRDIVRDR DAEIVVKDNG
181: RSCPPCHEVC KGRCWGPGSE DCQTLTKTIC APQCNGHCFG PNPNQCCHDE CAGGCSGPQD
241: TDCFACRHFN DSGACVPRCP QPLVYNKLTF QLEPNPHTKY QYGGVCVASC PHNFVVDQTS
301: CVRACPPDKM EVDKNGLKMC EPCGGLCPKA CEGTGSGSRF QTVDSSNIDG FVNCTKILGN
361: LDFLITGLNG DPWHKIPALD PEKLNVFRTV REITGYLNIQ SWPPHMHNFS VFSNLTTIGG
421: RSLYNRGFSL LIMKNLNVTS LGFRSLKEIS AGRIYISANR QLCYHHSLNW TKVLRGPTEE
481: RLDIKHNRPR RDCVAEGKVC DPLCSSGGCW GPGPGQCLSC RNYSRGGVCV THCNFLNGEP
541: REFAHEAECF SCHPECQPME GTATCNGSGS DTCAQCAHFR DGPHCVSSCP HGVLGAKGPI
601: YKYPDVQNEC RPCHENCTQG CKGPELQDCL GQTLVLIGKT HLTMALTVIA GLVVIFMMLG
661: GTFLYWRGRR IQNKRAMRRY LERGESIEPL DPSEKANKVL ARIFKETELR KLKVLGSGVF
721: GTVHKGVWIP EGESIKIPVC IKVIEDKSGR QSFQAVTDHM LAIGSLDHAH IVRLLGLCPG
781: SSLQLVTQYL PLGSLLDHVR QHRGALGPQL LLNWGVQIAK GMYYLEEHGM VHRNLAARNV
841: LLKSPSQVQV ADFGVADLLP PDDKQLLYSE AKTPIKWMAL ESIHFGKYTH QSDVWSYGVT
901: VWELMTFGAE PYAGLRLAEV PDLLEKGERL AQPQICTIDV YMVMVKCWMI DENIRPTFKE
961: LANEFTRMAR DPPRYLVIKR ESGPGIAPGP EPHGLTNKKL EEVELEPELD LDLDLEAEED
1021: NLATTTLGSA LSLPVGTLNR PRGSQSLLSP SSGYMPMNQG NLGESCQESA VSGSSERCPR
1081: PVSLHPMPRG CLASESSEGH VTGSEAELQE KVSMCRSRSR SRSPRPRGDS AYHSQRHSLL
1141: TPVTPLSPPG LEEEDVNGYV MPDTHLKGTP SSREGTLSSV GLSSVLGTEE EDEDEEYEYM
1201: NRRRRHSPPH PPRPSSLEEL GYEYMDVGSD LSASLGSTQS CPLHPVPIMP TAGTTPDEDY
1261: EYMNRQRDGG GPGGDYAAMG ACPASEQGYE EMRAFQGPGH QAPHVHYARL KTLRSLEATD
1321: SAFDNPDYWH SRLFPKANAQ RT